Literature DB >> 17497137

Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine.

Stephen A Varvel1, Billy R Martin, Aron H Lichtman.   

Abstract

RATIONALE: Recent evidence has provided support for the incentive-sensitization model of addiction, where repeated stimulation of neural reward circuits leads to a long-lasting sensitization of mesolimbic dopaminergic activity. This phenomenon has been demonstrated with many drugs of abuse, most often by measuring progressively increased activating effects of drugs on locomotor activity, thought to reflect an underlying neural sensitization. Whether cannabinoids, and in particular Delta(9)-tetrahydrocannabinol (THC), produce similar effects in this model is somewhat controversial, with mixed evidence in the literature.
OBJECTIVES: These experiments were conducted to determine whether behavioral sensitization could be established in mice after repeated exposure to THC. Sensitization to repeated methamphetamine treatment was used as a positive control.
METHODS: The effects of acute and repeated intermittent (every 3-4 days) treatment with THC or methamphetamine on locomotor activity were determined in Institute of Cancer Research (ICR) mice. Additional experiments with THC employed a dosing regimen that increased the number of injections, controlled for behavioral tolerance, examined different aspects of behavior, and used a different species (Sprague-Dawley rats).
RESULTS: Both methamphetamine and THC acutely increased activity. A robust dose-dependent sensitization was observed after intermittent treatment with methamphetamine but not with THC. Additionally, no evidence for behavioral sensitization to the effects of THC was found with any of the various protocols.
CONCLUSION: These data suggest that repeated THC treatment is less likely to produce behavioral sensitization than are other drugs of abuse. It appears that this phenomenon may only occur under very particular conditions, which raises doubts about its relevance to chronic cannabis users.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497137      PMCID: PMC2637562          DOI: 10.1007/s00213-007-0811-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain.

Authors:  D M Jackson; N E Andén; A Dahlström
Journal:  Psychopharmacologia       Date:  1975-12-31

2.  Reverse tolerance to ambulation-increasing effects of methamphetamine and morphine in 6 mouse strains.

Authors:  H Kuribara; S Tadokoro
Journal:  Jpn J Pharmacol       Date:  1989-02

3.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

4.  Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat.

Authors:  A J Pijnenburg; W M Honig; J M Van Rossum
Journal:  Psychopharmacologia       Date:  1975

5.  A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice.

Authors:  E Valjent; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

6.  Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice.

Authors:  C E Bass; B R Martin
Journal:  Drug Alcohol Depend       Date:  2000-08-01       Impact factor: 4.492

7.  Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine.

Authors:  J C Arnold; A N Topple; G E Hunt; I S McGregor
Journal:  Eur J Pharmacol       Date:  1998-07-31       Impact factor: 4.432

8.  The time course and significance of cannabis withdrawal.

Authors:  Alan J Budney; Brent A Moore; Ryan G Vandrey; John R Hughes
Journal:  J Abnorm Psychol       Date:  2003-08

9.  THC-induced place and taste aversions in Lewis and Sprague-Dawley rats.

Authors:  L A Parker; T Gillies
Journal:  Behav Neurosci       Date:  1995-02       Impact factor: 1.912

10.  Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex.

Authors:  J Chen; W Paredes; J H Lowinson; E L Gardner
Journal:  Eur J Pharmacol       Date:  1990-11-06       Impact factor: 4.432

View more
  7 in total

1.  Understanding Addiction Using Animal Models.

Authors:  Brittany N Kuhn; Peter W Kalivas; Ana-Clara Bobadilla
Journal:  Front Behav Neurosci       Date:  2019-11-29       Impact factor: 3.558

Review 2.  Do initial responses to drugs predict future use or abuse?

Authors:  Harriet de Wit; Tamara J Phillips
Journal:  Neurosci Biobehav Rev       Date:  2012-04-21       Impact factor: 8.989

Review 3.  Drug addiction.

Authors:  Zuzana Justinova; Leigh V Panlilio; Steven R Goldberg
Journal:  Curr Top Behav Neurosci       Date:  2009

4.  Previous exposure to delta9-tetrahydrocannibinol enhances locomotor responding to but not self-administration of amphetamine.

Authors:  James J Cortright; Daniel S Lorrain; Jeff A Beeler; Wei-Jen Tang; Paul Vezina
Journal:  J Pharmacol Exp Ther       Date:  2011-03-09       Impact factor: 4.030

Review 5.  Addiction is Not a Natural Kind.

Authors:  Jeremy Michael Pober
Journal:  Front Psychiatry       Date:  2013-10-04       Impact factor: 4.157

Review 6.  Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease.

Authors:  Debra A Kendall; Guillermo A Yudowski
Journal:  Front Cell Neurosci       Date:  2017-01-04       Impact factor: 5.505

7.  The Impact of Adolescent Alcohol Exposure on Nicotine Behavioral Sensitization in the Adult Male Neonatal Ventral Hippocampal Lesion Rat.

Authors:  Emily D K Sullivan; Liam N Locke; Diana J Wallin; Jibran Y Khokhar; Elise M Bragg; Angela M Henricks; Wilder T Doucette
Journal:  Front Behav Neurosci       Date:  2021-11-11       Impact factor: 3.558

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.